Stock Scorecard



Stock Summary for Enanta Pharmaceuticals Inc (ENTA) - $9.42 as of 11/20/2024 4:00:54 PM EST

Total Score

12 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ENTA

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ENTA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ENTA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ENTA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ENTA (29 out of 90)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0

Latest News for for ENTA

60 Degrees Pharmaceuticals Inc. ( SXTP ) Reports Q3 Loss, Misses Revenue Estimates 11/14/2024 8:25:00 PM
ElectroCore, Inc. ( ECOR ) Reports Q3 Loss, Tops Revenue Estimates 11/13/2024 10:15:00 PM
Journey Medical Corporation ( DERM ) Reports Q3 Loss, Tops Revenue Estimates 11/12/2024 10:25:00 PM
Enanta Pharmaceuticals ( ENTA ) Surges 5.6%: Is This an Indication of Further Gains? 10/2/2024 11:53:00 AM
Enanta Pharmaceuticals Reports Antiviral For Respiratory Syncytial Virus Reduces Virus Levels, Symptoms In Study - Enanta Pharma ( NASDAQ:ENTA ) 9/26/2024 6:00:00 PM
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer - Xenon Pharmaceuticals ( NASDAQ:XENE ) 8/12/2024 12:30:00 PM
Enanta Pharmaceuticals ( ENTA ) Reports Q3 Loss, Tops Revenue Estimates 8/5/2024 9:10:00 PM
Enanta Pharmaceuticals ( ENTA ) Soars 6.7%: Is Further Upside Left in the Stock? 7/15/2024 2:10:00 PM
Enanta Pharmaceuticals ( NASDAQ:ENTA ) Stock Rating Upgraded by StockNews.com 5/10/2024 6:18:00 AM
Enanta Pharmaceuticals ( ENTA ) Reports Q2 Loss, Tops Revenue Estimates 5/6/2024 9:10:00 PM

Financial Details for ENTA

Company Overview

Ticker ENTA
Company Name Enanta Pharmaceuticals Inc
Country USA
Description Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 6/30/2024
Next Earnings Date 2/5/2025

Stock Price History

Last Day Price 9.42
Price 4 Years Ago 42.10
Last Day Price Updated 11/20/2024 4:00:54 PM EST
Last Day Volume 158,736
Average Daily Volume 126,958
52-Week High 17.80
52-Week Low 8.51
Last Price to 52 Week Low 10.69%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -10.55
Free Cash Flow Ratio 0.87
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 4.92
Total Cash Per Share 10.86
Book Value Per Share Most Recent Quarter 7.03
Price to Book Ratio 1.36
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 2.77
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 2
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 21,188,600
Market Capitalization 199,596,612
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -66.20%
Annual Earnings Growth -9.91%
Reported EPS 12 Trailing Months -5.36
Reported EPS Past Year -4.12
Reported EPS Prior Year -6.37
Net Income Twelve Trailing Months -115,329,000
Net Income Past Year -133,816,000
Net Income Prior Year -121,755,000
Quarterly Revenue Growth YOY -4.90%
5-Year Revenue Growth -18.55%
Operating Margin Twelve Trailing Months -1.35

Balance Sheet

Total Cash Most Recent Quarter 230,085,000
Total Cash Past Year 369,910,000
Total Cash Prior Year 249,232,000
Net Cash Position Most Recent Quarter 230,085,000
Net Cash Position Past Year 369,910,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 216,735,000
Total Stockholder Equity Prior Year 321,334,000
Total Stockholder Equity Most Recent Quarter 148,915,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -100,331,000
Free Cash Flow Per Share Twelve Trailing Months -4.74
Free Cash Flow Past Year -112,212,000
Free Cash Flow Prior Year -86,907,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.39
MACD Signal -0.20
20-Day Bollinger Lower Band 8.73
20-Day Bollinger Middle Band 12.18
20-Day Bollinger Upper Band 15.63
Beta 0.57
RSI 28.47
50-Day SMA 12.66
150-Day SMA 32.07
200-Day SMA 38.50

System

Modified 11/21/2024 12:03:55 AM EST